ABSTRACT
Aims: Chronic myeloproliferative diseases[CMPD] are clonal diseases which may cause hemostatic and thrombotic abnormalities and progress to acute leukemia and characterized by increases in the number of mature and immature cells in the peripheral blood as a result of uncontrolled proliferation of one or more than one type of myeloerythroid cells in the bone marrow.The purpose of this study is to determine demographic features, the incidence of JAK2 mutation,disease characteristics and treatment strategies in patients with the diagnosis of CMPD
Methods: A total of 100 CMPD patients[essential thrombocytosis[ET],n=52;primary myelofibrosis [PMF], n=31 and polycythemia vera[PV],n=17] admitted to our clinic between February 2006 and February 2013 were included with the diagnosis of BCR/ABL-negative CMPD based on 2008 WHO criteria in whom JAK mutation was analyzed were included in the study. Age, gender, family history, secondary cancer, bleeding, history of thrombosis, whole blood cell counts, the presence of hepatomegaly and splenomegaly and other symptoms and signs at the time of diagnosis were evaluated. Besides, thrombotic and hemorrhagic history of the patients were assessed.The presence of JAK mutation in DNA samples was analyzed using Real-Time PCR
Results: Distribution of age and gender of the patients, besides family history, previous incidents of bleeding, thrombosis, secondary cancer, also blood hemoglobin,LDH values, platelet and white blood cell counts, constitutional symptoms, minor neurologic symptoms, presence of hepatomegaly and splenomegaly at the time of diagnosis.In our study, the incidence of JAK2 mutation was highest among cases with PMF[70.9 percent], followed by cases with PV[70.6 percent] and ET[51.9 percent].
Conclusion: The incidence of JAK2 mutation has offered a different perspective in BCR/ABL- negative cases with CMPD and has taken its place as an acceptable diagnostic factor.In our study, since a limited number of cases were analyzed in our study,the relationship between this mutation and CMPD should be confirmed by the studies with higher number of cases
ABSTRACT
Chronic lymphocytic leukemia [CLL] is a chronic lymphoproliferative hematological malignancy accompanied by a Chronic lymphocytic leukemia [CLL] is a chronic lymphoproliferative hematological malignancy accompanied by a monoclonal proliferation of mature B lymphocytes. Vitamin D is vital in calcium hemostasis in serum and skeletal system and is involved in several other cellular processes such as differentiation, proliferation, apoptosis, and angiogenesis. Vitamin D receptors were also demonstrated in normal or malignant hematopoietic cells. The correlation of low serum vitamin D levels with colorectal, breast, and other solid-organ neoplasms is well known. With regard to CLL, vitamin D inadequacy is related to bad prognosis, bad overall survival, and necessity to start treatment early. This study aimed to compare vitamin D levels of patients with early-stage CLL and controls and to examine its relationship with prognostic indicators. The study included 33 patients with early-stage CLL treated at Atatürk Training and Research Hospital Hematology Clinic between 2015 and 2017 and 34 healthy controls. Age and gender distribution in both groups was similar. Patients with <20 ng/mL vitamin D level were considered as vitamin D deficient. Vitamin D deficiency was detected in 26/33 patients with CLL and 16/34 controls. A statistically significant difference in vitamin D deficiency was found between these two groups [P = 0.003]. CLL cases were compared in terms of RAI stage, splenomegaly, hepatomegaly, and presence of B symptoms. However, no significant difference was observed. This study demonstrated that vitamin D levels of patients with early-stage CLL were significantly low in comparison with those of healthy population, in line with the literature. More comprehensive studies are required for assessing the effects of low vitamin D levels on the prognosis of patients with early-stage CLL
ABSTRACT
BACKGROUND/AIMS: Poor sleep quality (SQ) is associated with increased cardiovascular mortality and morbidity. Additionally, asymmetric dimethylarginine (ADMA) is an independent predictor of cardiovascular mortality and morbidity. However, no sufficient data regarding the relationship between ADMA levels and SQ have been reported. The goal of the current study was to evaluate the association between SQ and ADMA levels in normotensive patients with type 2 diabetes mellitus. METHODS: The study participants consisted of 78 normotensive type 2 diabetics. The SQ of all participants was assessed using the Pittsburgh Sleep Quality Index (PSQI). Patients with a global PSQI score > 5 were defined as "poor sleepers." Factors associated with poor SQ were analyzed using a multiple regression model. Serum ADMA levels were measured using high performance liquid chromatography. RESULTS: The median ADMA levels of the poor sleepers were increased compared with patients defined as good sleepers (5.5 [4.2 to 6.6] vs. 4.4 [2.9 to 5.4], p < 0.01, respectively). However, the L-arginine/ADMA ratio was decreased in poor sleepers (p < 0.01). Global PSQI scores were positively correlated with ADMA levels (p < 0.01) and negatively correlated with the L-arginine/ADMA ratio (p = 0.02). ADMA levels were correlated with sleep latency (p < 0.01) and sleep efficiency (p = 0.01). Logistic regression analysis showed that ADMA levels (odds ratio [OR], 1.68; 95% confidence interval [CI], 1.16 to 2.44; p = 0.01) and body mass index (OR, 1.15; 95% CI, 1.01 to 1.31; p = 0.04) were associated with poor SQ independently of glomerular filtration rate, sex, age, duration of diabetes, hemoglobin A1c, total cholesterol, and systolic blood pressure. CONCLUSIONS: Self-reported SQ was independently associated with ADMA levels in normotensive patients with diabetes mellitus.